Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 9/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.42 |
| ▸ | MET | P08581 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30890878 | 0.93 | CSF1R (0.45) | CSF1RPDGFRAKITPDGFRBTGFBR1 | |
| SCHEMBL16036512 | 0.93 | CSF1R (0.45) | CSF1RPDGFRAKITPDGFRBTGFBR1 | |
| SCHEMBL16036505 | 0.86 | TGFBR1 (0.45) | CSF1RPDGFRAKITPDGFRBTGFBR1 | |
| SCHEMBL16036508 | 0.86 | TGFBR1 (0.45) | CSF1RPDGFRAKITPDGFRBTGFBR1 | |
| SCHEMBL16038009 | 0.85 | CSF1R (0.52) | CSF1RPDGFRAPDGFRBTGFBR1MET | |
| SCHEMBL16037333 | 0.84 | CSF1R (0.45) | CSF1RPDGFRAKITPDGFRBAXL | |
| SCHEMBL13860835 | 0.83 | GAA (0.46) | AXLMETALDH1A1GAA | |
| SCHEMBL16038204 | 0.83 | KDR (0.49) | — | |
| SCHEMBL21772037 | 0.83 | KDR (0.51) | CSF1RPDGFRAPDGFRB | |
| SCHEMBL16037125 | 0.82 | TGFBR1 (0.43) | CSF1RPDGFRAKITPDGFRBAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309224-B2 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145029-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275016-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 5/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.